Health Care Equipment

CHRONOSCALE CORPORATION

Phoenix Asia

Sadot

Backblaze

Sobr Safe

Everquote

Apimeds Pharmaceuticals US

EZGO Tech

Selectquote

Sterling Infrastructure

Leverage Shares 2X Long CIFR Daily ETF

EKSO

HUMN

Hypershell, a Chinese startup, is developing lightweight exoskeletons aimed at enhancing human capability for outdoor and everyday use. By combining motors and sensors, their products assist with walking and climbing, focusing on aesthetics and ease of use to encourage consumer adoption. Targeting outdoor enthusiasts initially, Hypershell plans to expand into North America and Europe. The company faces challenges in reducing costs and validating scalable applications, with current prices ranging from $899 to $1,999. As technology advances, the transition to mainstream consumer use is expected to be gradual, emphasizing iterative development and user feedback.

TechNode

EKSO Bionics

Roundhill Humanoid Robotics ETF

Betting on human augmentation, will lightweight exoskeletons go mainstream?

Earnings Watch

EKSO Bionics | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 2.141 M

SBIO

Insider activity at EKSO BIONICS on March 20, 2026, saw COO Jason C Jones and CFO Jerome Wong each purchase 1,308 shares, indicating strong executive confidence. However, the company faces significant IP risks, including trade-secret infringement and dependence on co-owned patents, which could impact future innovations. Analysts view EKSO stock as Neutral due to ongoing losses and cash burn, despite some positive technical indicators. The current market cap is $37.06M, with a year-to-date price performance of 20.37%.

Tip Ranks

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Top EKSO BIONICS Insiders Make Bold Moves With Fresh Share Purchases

EKSO Bionics | 10-K: FY2025 Revenue Misses Estimate at USD 12.8 M

Reuters

Direxion S&P Biotech Bear 3X

Ekso Bionics Holdings Inc. Reports Initial Beneficial Ownership by Daniel Asher

ANIK

NBSE.ESC

Eikon Therapeutics, Inc is set to IPO on February 5, 2026, on NASDAQ under the ticker EIKN. The shares are expected to be priced between $16.00 and $18.00 each, with a 180-day insider lock-up period ending on August 4, 2026. The company focuses on developing innovative medicines for serious unmet medical needs.

fidelity

Anika Therap

ESC NEUBASE THERAPEUTI

Preview: Eikon Therapeutics, Inc Set To IPO Tomorrow

Ekso Bionics (EKSO) announced a private placement of $5.8 million on January 20, 2026, involving 5,852 shares of Series B preferred stock and warrants for up to 360,000 common shares. Each preferred share is valued at $1,000 and can be converted into common shares at any time.

Ekso Bionics prices $5.8M private placement

VTYX

FONR

FFIC

Halper Sadeh LLC is investigating potential violations of federal securities laws involving Ventyx Biosciences, FONAR Corporation, Sun Country Airlines, and Flushing Financial Corp. Shareholders are encouraged to contact the firm to discuss their rights and options regarding the sales of these companies. The firm may seek increased consideration for shareholders and offers legal services on a contingent fee basis. Interested parties can reach out to Halper Sadeh LLC for more information.

prnewswire

Ventyx Biosciences

Fonar

Flushing Financial

15:00 ET
			
			
				Halper Sadeh LLC Encourages VTYX, FONR, SNCY, FFIC Shareholders to Contact the Firm to Discuss Their Rights

EKSO BIONICS' COO, Jason C. Jones, sold 1,320 shares, valued at $12,210, raising concerns among investors. The stock experienced volatility following news of a non-binding merger with Applied Digital's cloud unit, shifting focus from exoskeletons to AI infrastructure. H.C. Wainwright downgraded EKSO, citing risks in strategic realignment amid ongoing financial losses. TipRanks' AI Analyst rates EKSO as Neutral, highlighting weak financial performance and potential upside from the merger, but with significant uncertainty. Current market cap stands at $29.01M with a YTD price performance of 10.30%.

Top Executive’s Surprise Stock Move Shakes Up EKSO BIONICS Investors

CHRONOSCALE CORPORATION(CHRN.US)